Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
105.40    2.20 (2.13%)
Bid:
105.40
Ask:
105.80
Spread: 0.40 (0.38%)
Market Cap: £172.80m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Interim Management Statement

6 May 2010 11:00

RNS Number : 4369L
Yule Catto & Co PLC
06 May 2010
 



6 May 2010

 

Yule Catto & Co plc 

 

Interim Management Statement

 

Yule Catto & Co plc, the international producer of speciality chemicals, today issues its Interim Management Statement for the period from 1 January to 31 March 2010

 

 

The Group has made a good start to the year with first quarter PBT comfortably ahead of last year.

 

Polymer Chemicals is the Group's main business, accounting for 88% of divisional operating profit in 2009 with 50% of its revenue in Asia and emerging markets. The business made a good start to the year. Volumes were over 10% up on prior year, strongly ahead of the weak first quarter of 2009. Volumes in Asia remain strong. Whilst Europe started slowly, in part due to the difficult weather conditions, demand strengthened through the quarter and this has continued into April. Monomer prices continued to rise through the quarter and the business has continued to seek to recover these increases in the market place.

 

Pharma Chemicals has continued to trade weakly, with profits in the first quarter below prior year, though the business has a good current forward order book.

 

William Blythe, the remaining Impact Chemicals business was ahead of last year as expected.

 

Net debt rose during the quarter, as the improving demand position absorbed additional working capital, but is still comfortably below £100 million. We are still in the process of completing the announced sale of the Finewaters adhesive business, which will deliver a further reduction in debt of £11 million when concluded.

 

Looking forward in Polymers we expect to see continuing strong demand in Asia and modest volume improvement in Europe. Monomer prices have continued to rise during the second quarter and work is in hand to recover these increases. Pharma, after the slow start, is likely to trade a little below last year, whilst William Blythe will be ahead. Overall trading is in line with the Board's previous expectations for the full year.

 

 

ENQUIRIES:

 

YULE CATTO & Co plc

Tel: 01279 442791

Adrian Whitfield, Chief Executive

David Blackwood, Finance Director

HOGARTH

Tel: 020 7357 9477

John Olsen

Andrew Jaques

Ian Payne

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSLIFLTEFIRIII
Date   Source Headline
1st Jun 20262:42 pmRNSHolding(s) in Company
29th May 20263:57 pmRNSTotal Voting Rights
22nd May 20265:21 pmRNSNotice of AGM
8th May 20264:33 pmRNSAdmission to Trading
7th May 20261:51 pmRNSApplication for Admission to Trading
5th May 20264:25 pmRNSHolding(s) in Company
30th Apr 20264:40 pmRNSAnnual Financial Report
30th Apr 20263:17 pmRNSDirector/PDMR Shareholding
30th Apr 202611:25 amRNSDirector/PDMR Shareholding
30th Apr 20267:01 amRNSChange of Chief Financial Officer
30th Apr 20267:00 amRNSFinal Results
19th Mar 20267:00 amRNSTrading and refinancing update
11th Feb 20261:46 pmRNSStatement re potential refinancing
29th Jan 20267:00 amRNSTrading Statement - Winter 2026
27th Jan 20264:51 pmRNSHolding(s) in Company
26th Jan 20264:23 pmRNSHolding(s) in Company
18th Dec 20257:00 amRNSReceivables purchasing arrangement
12th Dec 20259:30 amRNSDirectorate change
12th Nov 20257:00 amRNSDirector/PDMR Shareholding
5th Nov 20251:28 pmRNSHolding(s) in Company
23rd Oct 20257:00 amRNSTrading statement - Autumn 2025
14th Oct 20257:00 amRNSAppointment of joint corporate broker
4th Sep 20255:17 pmRNSHolding(s) in Company
11th Aug 20258:00 amRNSDirector/PDMR Shareholding
6th Aug 20259:45 amRNSDirector/PDMR Shareholding
5th Aug 202511:57 amRNSDirector/PDMR Shareholding
5th Aug 202511:00 amRNSDirectorate Change
5th Aug 20257:00 amRNSInterim results
4th Jul 20257:01 amRNSDirector/PDMR Shareholding
1st Jul 20257:00 amRNSCovenant update
30th Jun 20257:00 amRNSDirectorate Changes
27th Jun 20254:21 pmRNSHolding(s) in Company
2nd Jun 20257:00 amRNSDivestment of William Blythe completed
6th May 20257:00 amRNSDivestment of William Blythe
1st May 20254:18 pmRNSResults of AGM
1st May 20257:00 amRNSTrading Statement - Spring 2025
15th Apr 20253:00 pmRNSHolding(s) in Company
28th Mar 20257:30 amRNSDirector/PDMR Shareholding
27th Mar 20257:30 amRNSDirector/PDMR Shareholding
25th Mar 20254:23 pmRNSAnnual Report and Notice of AGM
25th Mar 202511:43 amRNSDirector/PDMR Shareholding
25th Mar 202511:41 amRNSDirector/PDMR Shareholding
24th Mar 20257:30 amRNSHolding(s) in Company
17th Mar 20259:00 amRNSDirector/PDMR Shareholding
17th Mar 20259:00 amRNSDirector/PDMR Shareholding
11th Mar 20257:00 amRNSFinal Results
6th Mar 20258:32 amRNSDirector Declaration
13th Feb 20257:00 amRNSHolding(s) in Company
28th Jan 202510:30 amRNSDirector/PDMR Shareholding
28th Jan 20257:00 amRNSWinter trading statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.